Karima is Senior Consultant at SFL and advises clients in strategic R&D planning and alliance management Japan.
She has over 30 years of experience in pharmaceutical R&D, strategic planning and BD&L at major pharmaceutical companies. Karima has been instrumental in the creation of the world’s biggest public-private partnership in the life sciences, the Innovative Medicines Initiative (IMI), and been essential in the first approval of an antibody-drug conjugate for breast cancer in Japan. Karima has been involved in all phases of the partnering process in the area of cardiovascular, renal and metabolic diseases and of gastrointestinal diseases.
She enjoys working at the interfaces between research and business functions, between public and private stakeholders, and between cultures to align R&D strategies and market needs.
Karima holds a PhD in Pharmacology from the University Louis Pasteur in Strasbourg, France and an MBA from Duke University, Fuqua School of Business in the US.
SFL Regulatory Affairs & Scientific Communication Ltd.